<?xml version="1.0" encoding="UTF-8"?>
<p id="Par8">Dose-related asymptomatic prolongation in the PR interval with atazanavir has been observed in clinical studies [
 <xref ref-type="bibr" rid="CR17">17</xref>, 
 <xref ref-type="bibr" rid="CR18">18</xref>]. It should be used with caution as prescribed with medicinal products that have the potential to increase the QT interval and/or in patients with preexisting risk factors (bradycardia, long congenital QT, and electrolyte imbalances) [
 <xref ref-type="bibr" rid="CR19">19</xref>].
</p>
